1 of 1
Story summary
- Moderna and Merck announced their Phase 3 autogene trial met its primary endpoint in melanoma.
- The therapy uses AI to sequence each tumor and design a personalized dose within four-to-eight weeks.
- Combination with Merck’s Keytruda improved recurrence-free survival.
- Combination with Keytruda reduced distant-metastasis risk compared with Keytruda alone.
- Overall survival results remain pending, leaving the final analysis incomplete.